Menu Search
Equities

Novartis AG

NOVNEE:SWX

Novartis AG

Actions
  • Price (CHF)98.85
  • Today's Change0.32 / 0.32%
  • Shares traded400.00k
  • 1 Year change+6.05%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 15:41 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		NOVN:SWX since
announced		Transaction
value
IFM Due IncAnnounced13 Mar 202413 Mar 2024Announced13.06%835.00m
Cytokinetics IncRumoured08 Jan 202408 Jan 2024Rumoured9.53%--
Calypso Biotech BVAnnounced08 Jan 202408 Jan 2024Announced9.53%425.00m
SanReno TherapeuticsDeal completed05 Jan 202405 Jan 2024Deal completed10.23%--
Data delayed at least 15 minutes, as of Sep 20 2024 16:31 BST.

Institutional shareholders

0.00%Per cent of shares held by top holders
HolderShares% Held
Pyrford International Ltd.as of 31 Dec 202379.13k0.00%
LUKB Expert Fondsleitung AGas of 31 Jul 202364.69k0.00%
Voya Investment Management Co. LLCas of 31 Jul 202445.96k0.00%
Swiss Rock Asset Management AGas of 30 Jun 202319.61k0.00%
Nomura Asset Management Co., Ltd.as of 30 Aug 202410.77k0.00%
Morgan Stanley AIP GP LPas of 30 Jun 2024237.000.00%
JPMorgan Asset Management (China) Co Ltd.as of 31 Dec 20230.000.00%
More ▼
Data from 31 Jul 2023 - 31 Aug 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.